Nearly 2 out of 5 people with diabetes who could benefit from statin therapy to lower their risk of future heart attack, stroke and related death were not prescribed one, according to a research letter published in the Journal of the American College of Cardiology. The analysis also showed wide variation in statin use across cardiology practices included in the study.

C. R. Bard Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption (IDE) supplemental application to modify the primary endpoint to a six-month time point for the Lutonix 014 Drug Coated Balloon PTA Catheter (DCB). The Lutonix 014 device is currently the only DCB in an IDE clinical trial in the United States for treatment of arteries below the knee (BTK).

Smartphone communication among medical teams at different hospitals can significantly reduce the time it takes for heart attack patients to get lifesaving treatment after a hospital transfer, according to a research letter published in the Journal of the American College of Cardiology.

A Google search for heart conditions will now prominently display important questions patients should ask their doctor based on clinical guidelines developed by the American College of Cardiology.

Technology advances coupled with increased use of social media and personal devices could offer new possibilities for treating patients and improving outcomes, but new approaches must be rigorously evaluated, according to U.S. Food and Drug Administration Commissioner Robert M. Califf, M.D., MACC. Califf’s comments appeared in a column  published in the Journal of the American College of Cardiology.

New data presented at the Vascular Interventional Advances (VIVA) conference demonstrated the durability, consistency and safety of Medtronic’s IN.PACT Admiral drug-coated balloon. The presentation included three-year results from the pivotal IN.PACT SFA Trial and one-year, real-world results from the full clinical cohort of the IN.PACT Global Study.

4Tech Inc. announced that its TriCinch device has been used in the world’s first-ever successful transcatheter tricuspid valve repair without the use of transesophageal echocardiography (TEE) or general anesthesia to successfully treat tricuspid regurgitation (TR). The TriCinch implant took less than one hour and allowed substantial reduction of TR.

September 22, 2016 — GE Healthcare announced the global commercial launch of its new generation of high-end portable compact cardiovascular ultrasound, the Vivid iq, at the European Society of Cardiology (ESC) Congress in Rome in August.

Transesophageal Echo, TEE. Interventional echocardiography, interventional echo, Philips, CX50
GE healthcare, ultrasound, Transesophageal Echo, TEE. Interventional echocardiography, interventional echo
Transesophageal Echo, TEE. Interventional echocardiography, interventional echo, Philips, echonavigator
GETransesophageal Echo, TEE. Interventional echocardiography, interventional echo, Mitraclip

The rapid growth of transcatheter structural heart procedures and the need for increased use of echocardiography as an integral part of the structural heart team, has given rise to the new subspecialty of interventional echocardiography. While interventional echo has been recognized with a growing number of specialty training sessions provided by the American Society of Echocardiography (ASE) and Transcatheter Cardiovascular Therapeutics (TCT) annual meetings, the requirements for these specialists are still evolving. 
Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now